History
Federal regulatory agencies such as the U.S. Environmental Protection Agency and the U.S. Food and Drug Administration evaluate all available toxicity data on specific chemicals or drugs to establish potential human risk through their use or exposure to them. For these agencies and other groups with human health interests, specific types of data are needed to best provide an adequate chemical toxicologic evaluation. Two sources of the more critical data are epidemiologic studies and the long-term rodent bioassays.
The most relevant data come from epidemiologic studies because they associate human health effects with environmental conditions. When a single environmental agent can be shown to be directly related to a specific health problem in an exposed population, the risk to humans for that agent is clear. The fundamental limitation of epidemiology is that it is difficult to relate a health problem to one environmental agent because most exposures are to mixtures of agents and there is an inherently low power to detect an effect. In addition these studies are retrospective evaluations of hazards (1) . An additional complication to the interpretation is that any study must account for differences in lifestyles within the exposed population.
In contrast, animal studies allow single-agent evaluations using appropriate exposure routes under controlled environmental conditions and these studies may be prospective. 
Study Objectives
Based on the transgenic mice study data (10, 11) Scientists from both government and the private sector were solicited for comments on the U.S. NTP plan to evaluate the potential of the transgenic mouse models and the set of chemicals selected for these initial studies.
Specific chemicals chosen for the initial U.S. NTP transgenic mouse studies and the rationale for their selection are listed in Table 2 together with the results from other U.S. NTP studies. The U.S. NTP studies described are currently under way. Preliminary data from these and additional studies completed by NIEHS scientists (10, 11) are encouraging and have stimulated the U.S. NTP to plan future transgenic model studies.
Future Studies
Because these studies require fewer animals and shorter exposure times, the use of transgenic models to identify carcinogens has generated interest among government and industry scientists. The U.S. Food and Drug Administration has decided to accept data from transgenic models in lieu of traditional mouse bioassay data for new drug registrations. Their decision is in keeping with the mission objectives of the International Congress on Harmonization to examine whether the need for long-term studies in two species could be reduced (15) . The U.S. NTP is participating in efforts by the pharmaceutical industry and other federal agencies to examine the response of four transgenic in vivo models systems including the Tg.AC and the heterozygous p53def mice.
